


Knee Osteoarthritis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest Drug Approvals | DelveInsight

DelveInsight's Knee Osteoarthritis Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NEVADA, UNITED STATES, March 26, 2024 /EINPresswire.com/ -- DelveInsight's "Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2032" report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.



To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Knee Osteoarthritis Market Forecast](#)

Some of the key facts of the Knee Osteoarthritis Market Report:

The Knee Osteoarthritis market size was valued approximately USD 13 billion in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

Anticipated launch of potential Knee Osteoarthritis therapies by notable companies, including Techfields (X0002), Taiwan Liposome Company (TLC599), Centrexion Therapeutics (CNTX-4975), Biosplice Therapeutics (Lorecivivint), Ampio Pharmaceuticals (Ampion), Paradigm Biopharmaceuticals (Zilosul), Grünenthal (RTX-GRT7039/Resiniferatoxin), Naturecell (JointStem), and other contenders, might contribute to the market's expansion of Knee Osteoarthritis in the upcoming years, supported by an expected rise in the prevalent population suffering from knee osteoarthritis.

In 2021, the total prevalent population diagnosed with symptomatic Knee Osteoarthritis across the seven major markets reached 47,874,567. The United States reported the highest prevalence with 17,660,391 cases, while the combined cases in EU4 and the UK accounted for 19,946,245 cases.

According to the assessment, a greater proportion of mild cases of knee Osteoarthritis was identified across the 7 Major Markets (7MM) in 2021, followed by moderate knee Osteoarthritis. In the United States specifically, the highest number of cases in 2021 was reported for mild knee osteoarthritis, with 7,373,858 instances, followed by moderate Knee Osteoarthritis, totaling 6,562,734 cases

In the European Union (EU4) and the United Kingdom (UK) in 2021, the most significant percentage of cases was observed in the age group of 70 years and above, followed by the age categories of 60–69 years and 50–59 years. Specifically, there were 638,280, 1,735,323, 4,328,335, 4,807,045, and 8,437,262 cases documented in the age groups of 18–39 years, 40–49 years, 50–59 years, 60–69 years, and 70 years and above, respectively.

Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others

Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others

The Knee Osteoarthritis epidemiology based on gender analyzed that females are most commonly affected than males in case of Knee Osteoarthritis

The Knee Osteoarthritis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

Knee Osteoarthritis Overview

Osteoarthritis of the knee, also known as degenerative joint disease, typically occurs when the articular cartilage undergoes gradual structural deterioration, often due to regular wear and tear. This condition can be categorized into primary and secondary forms and is predominantly observed among older individuals.

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/knee-osteoarthritis-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Knee Osteoarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed

patient pool and future trends.

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Knee Osteoarthritis

Prevalent Cases of Knee Osteoarthritis by severity

Gender-specific Prevalence of Knee Osteoarthritis

Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ [Knee Osteoarthritis Epidemiology Forecast](#)

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Knee Osteoarthritis Therapies and Key Companies

Retatrutide: Eli Lilly and Company

JointStem: Nature Cell Co. Ltd.

Semaglutide: Novo Nordisk A/S

FX201: Flexion Therapeutics, Inc.

RTX-GRT7039: Grünenthal GmbH

TTAX03: Tissue Tech Inc.

TG-C: Kolon TissueGene, Inc.

SL-1002: Saol Therapeutics Inc

PTP-001: Bioventus LLC

StroMel: Akan Biosciences, LLC

GNSC-001: Genascence Corporation

IMM01-STEM: Immunis, Inc.

RHH646: Novartis

Lorecivivint: Biosplice Therapeutics

Resiniferatoxin: Sorrento Therapeutics, Inc.

DFV890: Novartis

Celltex- AdMSCs: Celltex Therapeutics Corporation

Micronized DHACM: MiMedx Group, Inc./Rho, Inc.

X0002: Techfields Pharma Co. Ltd

CNTX-4975: Centrexion Therapeutics

TLC599: Taiwan Liposome Company

Amniofix: MiMedx

Ampion: Ampio Pharmaceuticals

Organogenesis: ReNu

Cartistem: Medipost

Knee Osteoarthritis Market Strengths

Now companies are investing heavily in developing disease modifying therapies for the treatment of knee osteoarthritis, which will fulfill a major unmet need.

Many key players are developing cell therapies for knee osteoarthritis, which are in various stages of development. These therapies, if approved, may provide better treatment options as it can slow disease progression and may possibly cure the disease.

Knee Osteoarthritis Market Opportunities

For the treatment of Knee OA, usage of opioids can be seen. The majority of patients/ physicians are eagerly waiting for nonopioids options and key players can target this lucrative segment of the market, while others are already developing therapies for the same.

Scope of the Knee Osteoarthritis Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Knee Osteoarthritis Companies: Bioventus LLC, Akan Biosciences, LLC, Genascence Corporation, Immunis, Inc., Novartis, Biosplice Therapeutics, Sorrento Therapeutics, Inc., Novartis, Celltex Therapeutics Corporation, MiMedx Group, Inc., Rho, Inc., Techfields Pharma Co. Ltd, Eli Lilly and Company, Nature Cell Co. Ltd., Novo Nordisk A/S, Flexion Therapeutics, Inc., Grünenthal GmbH, Tissue Tech Inc., Kolon TissueGene, Inc., Saol Therapeutics Inc, Centrexion Therapeutics, Taiwan Liposome Company, MiMedx, Ampio Pharmaceuticals, ReNu, Medipost, and others

Key Knee Osteoarthritis Therapies: TP-001, StroMel, GNSC-001, IMM01-STEM, RHH646, Lorecivivint, Resiniferatoxin, DFV890, Celltex- AdMSCs, Micronized DHACM, X0002, Retatrutide, JointStem, Semaglutide, FX201, RTX-GRT7039, TTAX03, TG-C, SL-1002, CNTX-4975, TLC599, Amniofix, Ampion, Organogenesis, Cartistem, and others

Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies

Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG

Matrix, Market entry strategies

Knee Osteoarthritis Unmet Needs, KOL's views, Analyst's views, Knee Osteoarthritis Market Access and Reimbursement

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ [Knee Osteoarthritis Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Knee Osteoarthritis Market Report Introduction
2. Executive Summary for Knee Osteoarthritis
3. SWOT analysis of Knee Osteoarthritis
4. Knee Osteoarthritis Patient Share (%) Overview at a Glance
5. Knee Osteoarthritis Market Overview at a Glance
6. Knee Osteoarthritis Disease Background and Overview
7. Knee Osteoarthritis Epidemiology and Patient Population
8. Country-Specific Patient Population of Knee Osteoarthritis
9. Knee Osteoarthritis Current Treatment and Medical Practices
10. Knee Osteoarthritis Unmet Needs
11. Knee Osteoarthritis Emerging Therapies
12. Knee Osteoarthritis Market Outlook
13. Country-Wise Knee Osteoarthritis Market Analysis (2019–2032)
14. Knee Osteoarthritis Market Access and Reimbursement of Therapies
15. Knee Osteoarthritis Market Drivers
16. Knee Osteoarthritis Market Barriers
17. Knee Osteoarthritis Appendix
18. Knee Osteoarthritis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/698890857>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.